Löffler B M, Bohn E, Hesse B, Kunze H
Arzneimittelforschung. 1987 May;37(5A):618-21.
The effects of the antiinflammatory drug benzydamine (Tantum) on phospholipase activities were determined in vitro, employing various enzyme preparations (rat liver plasma membranes, endoplasmic reticulum, lysosomes; human seminal plasma) and stereospecifically radiolabeled phosphatidylethanolamines as substrates. Fatty acid release from the sn-2 position was inhibited at drug concentrations above 10(-5) mol/l. Concerning the mode of inhibition, a mixed type was found for the soluble phospholipase A2. Impaired fatty acid release from the sn-2 position might contribute to the mechanism of antiinflammatory action of benzydamine by rendering less free precursor acid available for the synthesis of eicosanoids. Fatty acid release from the sn-1 position was inhibited at benzydamine concentrations from 10(-6)-10(-2) mol/l only in lysosomes, whereas in plasma membranes and endoplasmic reticulum it was stimulated, maximally (at 10(-3) mol/l) about 25% and 50%, respectively.
使用各种酶制剂(大鼠肝细胞膜、内质网、溶酶体;人类精浆)以及立体特异性放射性标记的磷脂酰乙醇胺作为底物,在体外测定了抗炎药物苄达明(坦通)对磷脂酶活性的影响。当药物浓度高于10^(-5)mol/L时,sn-2位的脂肪酸释放受到抑制。关于抑制模式,发现可溶性磷脂酶A2为混合型抑制。sn-2位脂肪酸释放受损可能通过减少可用于合成类花生酸的游离前体酸,从而有助于苄达明的抗炎作用机制。仅在溶酶体中,当苄达明浓度为10^(-6) - 10^(-2)mol/L时,sn-1位的脂肪酸释放受到抑制,而在细胞膜和内质网中则受到刺激,最大刺激程度(在10^(-3)mol/L时)分别约为25%和50%。